This record provides bibliographic details and links to the original research. An editorial study breakdown is not available.
What the researchers found
A novel solid lipid nanoparticle formulation co-delivering LL37 and Serpin A1 at synergistic ratios significantly accelerated wound closure in fibroblast and keratinocyte cells and enhanced antibacterial activity against Staphylococcus aureus and Escherichia coli compared to individual treatments.
Why it matters
This approach addresses challenges in chronic wound treatment by providing controlled, sustained delivery of therapeutic peptides that both promote healing and combat infection, potentially reducing reliance on toxic antibiotics.
How the study worked
The study developed solid lipid nanoparticles encapsulating LL37 and Serpin A1 at specific ratios. In vitro experiments assessed wound closure in BJ fibroblast and keratinocyte cells and antibacterial efficacy against S. aureus and E. coli, comparing combined treatment to single agents.
What this study cannot tell us
The study was conducted in vitro, so results may not fully translate to clinical wound healing in humans; the study type and evidence strength were not specified.
Read the original research
Nanoparticles Encapsulated with LL37 and Serpin A1 Promotes Wound Healing and Synergistically Enhances Antibacterial Activity.
Molecular pharmaceutics, 13(7), 2318-31
Citation
Fumakia, Miral; Ho, Emmanuel A. (2016). Nanoparticles Encapsulated with LL37 and Serpin A1 Promotes Wound Healing and Synergistically Enhances Antibacterial Activity.. Molecular pharmaceutics, 13(7), 2318-31. https://doi.org/10.1021/acs.molpharmaceut.6b00099